Biocon
Biocon Biologics intends to advance access to more economical insulin for patients of diabetes in the US market, as the organization, with its partner Viatris, has received a license for Semglee (insulin glargine-yfgn injection) as the first substitute biosimilar insulin.
The interchangeable Semglee insulin, which will allow substitution of Semglee for the reference insulin, Lantus, at the drugstore counter, will be announced before the end of the year and commercial arrangements for that are ongoing.
Biologics, through Viatris, is qualified to have exclusivity for 12 months before the United States Food and Drug Administration (USFDA) can permit another biosimilar interchangeable to Lantus.
Read More News: Click Here
